(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) (THE CONVERSATION) Takeaways - Scientists have made progress growing human liver in the lab. - The challenge has been to direct stems cells to grow into a mature, functioning adult organ.
Stem cell treatment promise sells pregnant parents on cord blood banks Arizona Republic Moments after Linda Buzans son Luca is born, her OB-GYN goes to work.
WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors
- Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion - - Sickle cell disease: All three patients were free of vaso-occlusive crises with 3 to 15 months of follow-up after CTX001 infusion - - Nineteen patients have been dosed with CTX001 across both programs - - The New England Journal of Medicine publishes CTX001 manuscript containing the first report of investigational use of CRISPR/Cas9-based gene editing to treat inherited diseases in humans - ZUG, Switzerland and CAMBRIDGE, Mass.
SOUTH SAN FRANCISCO, Calif., Dec.
As you were browsing http://www.streetinsider.com something about your browser made us think you were a bot. If you are interested in http://www.streetinsider.com content, APIs are available. Please contact us here http://www.streetinsider.com/signup_content.php After completing the CAPTCHA below, you will immediately regain access to http://www.streetinsider.com
WASHINGTON, Dec.
What are the emerging opportunities in the Circulating Tumor Cells and Cancer Stem Cells Market? Currently, significant business sectors are going through changes.
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc
3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host Disease Six Doses of FT516 were Well-tolerated with No FT516-related Grade 3 or Greater Adverse Events Reported by Investigators Management to Host Virtual Event Entitled The Power of hnCD16 Today at 4:30 PM Eastern Time SAN DIEGO, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced positive interim data from the Companys dose escalation Phase 1 study of FT516 in combination with rituximab for patients with relapsed / refractory B-cell lymphoma.
Recent Comments